Transforming Wound Care Through Marine Science

Omeza® Holdings, Inc. is a U.S.-based ocean biotechnology company developing and commercializing marine-derived peptides and lipid products, with an FDA-cleared product, OCM™, already on the market and ongoing clinical programs to expand reimbursement and indications. Omeza products are formulated and manufactured in the USA.

Frame 1686551561
OVERVIEW

Our Pioneering Technologies

Corporate media room and clinical press announcement feature thumbnail image

Omeza combines compelling clinical validation with a scalable commercial model addressing a large and underserved market. Its use of sustainably sourced, marine-derived biological compounds positions the company at the forefront of a new generation of regenerative wound care solutions.

Omeza’s lead product, OCM™, is an FDA-cleared drug-device wound matrix derived from marine lipids and cold-water fish peptides. Applied in various settings, it reduces inflammation, disrupts bacterial biofilm, and supports tissue regeneration, offering a highly effective and cost-efficient alternative to traditional skin grafts.

OUR PURPOSE

Vision & Mission Statement

Omeza mission icon representing accessible and sustainable advanced wound care

Our Mission

To make advanced wound care accessible, sustainable and cost-effective

Omeza goal icon representing new standard of care for skin ulcers

Our Goal

To become the new standard of care for skin ulcers and hard-to-heal wounds

Omeza approach icon representing simple safe sustainable clinically proven healing

Our Approach

Simple, safe, sustainable and clinically-proven

UN SUSTAINABLE DEVELOPMENT GOALS
sdg-3
sdg-8
sdg-12
sdg-13
sdg-14
OUR MISSION

Restoring Skin Integrity

Wound Management & Prevention (WMP) Journal selected Omeza for a ‘Top Innovation in Wound Care 2022’ Award for the Omeza products bundle. At the core of this award-winning system is the Omeza® Complete Matrix Rx, engineered to decrease inflammation, increase proliferation, support remodeling, and reduce biofilm impact at any site of care.

View More
award-badge
SUSTAINABILITY

Our Natural Ingredients Deliver On Our Commitment To A Sustainable Future Of Wound Care

Omeza’s proprietary formulations include omega-3-, -6, and -9 oils and nutrients in a rapidly penetrating delivery system.

By prioritizing marine-derived biotechnology, waste upcycling and sustainable sourcing, those ingredients represent the pinnacle of the circular Blue Economy by utilizing discarded fish components. This directly aligns with the US National Strategy for a Sustainable Ocean Economy and the broader US Blue Economy initiatives.

Frame 1686551561 (1)
fish-icon

Hydrolyzed Fish Collagen

Sourced from North Atlantic white fish, it acts as a structural scaffold that allows new skin and tissue to regenerate.

drop-icon

Cod Liver Oil

Provides a rich source of vitamins (A, C, D, E) and serves as an anhydrous skin protectant to maintain a moist healing environment and support natural barrier repair.

molecule-icon

Omega Fatty Acids

Includes naturally occurring Omega 3, 6, and 9 to help decrease inflammation, manage bacterial contamination (like biofilms), and support tissue remodeling.

OUR HISTORY

The History Of Omeza Holdings, Inc.

Frame 1686551591

Research began into the unique wound healing properties of marine life at the world-renowned Mote Marine Laboratory in Sarasota, FL, USA.

2013

Omeza LLC was formed to explore different therapeutic applications in wound care and dermatology, utilizing advanced chemical engineering to develop its core formulations.

2014

Omeza’s lead product, OCM™, was FDA cleared in September 2021 as a 510(k) bioactive device, with instructions for use in hard-to-heal chronic wounds and acute wounds.

2021

Omeza LLC converted to Omeza Holdings Inc., a registered corporation, in January 2022. This corporate structure allows for further development globally of multiple therapeutic applications of OMEZA’s proprietary technology.

2022

By early 2025, Omeza had published 7 peer-reviewed publications on OCM™, studying 200 patients with a variety of very serious hard-to-heal wounds.

2025

Omeza concluded its first Series A financing in April.

2026

Connect with Our Experts

Direct your inquiry to the appropriate Omeza division, clinical, scientific, or corporate, and let's advance the future of wound care together.

Contact Us
COMPLETE WOUND CARE, DELIVERED SIMPLY. COMPLETE WOUND CARE, DELIVERED SIMPLY. COMPLETE WOUND CARE, DELIVERED SIMPLY. COMPLETE WOUND CARE, DELIVERED SIMPLY.